100? 200!!!!!!!!
The weight loss pill war is heating up with a new player entering the arena! VKTX-2735 is rocking it with its amazing safety profile and clear dose response. This means there's room to up the dosage for even better weight loss results! Can't wait for that!
$Novo-Nordisk A/S(NVO)$ Sales of Semaglutide have already hit a whopping $21.01 billion! $Eli Lilly(LLY)$ Tirzepatide sales reached $5.163 billion in 2023. If VKTX-2735 can grab just a slice of that market share with its dose response, easily taking $15 billion, its current market cap of less than $10 billion is a total steal! It's like $Viking Therapeutics(VKTX)$ hitting $200 is inevitable! đŞđ
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments